Psychedelics: Therapeutic Agents or Not?
Tuesday, September 25, 2025, 12:00 pm – 1:00 pm ET
This webinar will provide an integrated overview of the scientific, regulatory, and translational landscape shaping the development of psychedelic-based therapeutics. Topics will include key nonclinical findings, the assessment of toxicity data to inform
clinical trial design, and regulatory expectations for progressing through the FDA approval pathway. Attendees will gain insights into the effects of psychedelic products that may impact regulatory acceptance or commercial viability, including duration
of effect, dosing paradigms, safety liabilities, and the economic impact of treatment models.
Moderator
Kevin Murnane, PhD, LSU Health Shreveport
Marcus S. Delatte, PhD, Allucent
Speakers
Bob Discordia, PhD, EQUULUS Therapeutic
“Realities for the Development and Commercialization of Psychedelic-Based Therapeutics”
Kevin Murnane, PhD, LSU Health Shreveport
”Psychedelics as Pharmacotherapeutic Agents for Stimulant Use Disorder”
Marcus S. Delatte, PhD, Allucent
“Psychedelics: Assessing and Managing Product Risks”